RxDoctor Payments DataLook up a doctor →

Benjamin Osborne

Neurology · Washington, DCNPI 1750310504

Payments from drug & device makers

$1,499,381in general payments, 2019–2025

Across 969 payments — averaging $1547.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$468K
  • Genentech, Inc.$368K
  • Amgen$223K
  • Biogen$187K
  • UCB SA$68K
  • Alkermes, Inc.$66K
  • plus $120K from 14 others

What the payments were for

  • Consulting fees$141,82019%
  • Speaking & faculty fees$530,14371%
  • Travel & lodging$51,2387%
  • Food & beverage$22,8673%
  • Education$3930%
  • Gifts$790%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,499,381 in reported general payments places this provider in the 90th percentile of 113 neurology providers in District of Columbia.

See all neurology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$76,726
Medicare patients
298
Services billed
538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab26$1,425,333
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5027$202,398
EnspryngSatralizumab-Mwge11$177,602
Dalfampridine ErDalfampridine13$5,051
Modafinil21$2,682
Acetazolamide24$2,651
Pyridostigmine Bromide21$2,387
Baclofen32$1,283
Gabapentin74$1,201
Pregabalin34$1,110
Duloxetine Hcl25$1,100
Mycophenolate Mofetil14$544
Azathioprine11$403
Levetiracetam17$329
Oxycodone Hcl15$304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$467,562$1,425,33326 claims
Genentech USA, Inc.Enspryng$42,322$177,60211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 113 neurology providers in District of Columbia.

Other neurology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →